Group 1 - The core viewpoint of the articles highlights the growth potential of China's pharmaceutical and biotechnology industry, driven by multiple factors including increasing healthcare spending and a rising elderly population [1][2] - The compound annual growth rate (CAGR) for China's oncology drug market is projected to reach 12.4% from 2023 to 2030, significantly higher than the global average of 8.4% [1][2] - The Hang Seng Biotechnology Index, which tracks the performance of the largest 30 biotech companies listed in Hong Kong, has seen an 83% increase year-to-date, outperforming the Hang Seng Composite Index, which rose by 31% in the same period [1] Group 2 - China's healthcare expenditure as a percentage of GDP was 5.9% in 2022, which is lower than many G7 countries, indicating room for growth as disposable income is expected to rise at a CAGR of 5.3% from 2024 to 2028 [2] - The aging population in China is projected to increase the proportion of individuals aged 60 and above from 21% in 2024 to 42% by 2054, which is expected to drive up healthcare spending [2] - The Chinese government is placing greater emphasis on innovative drugs compared to generic drugs, with the CAGR for the innovative drug market projected at 7.9% from 2023 to 2028, while the generic drug market is expected to grow at a CAGR of 3.8% [2]
恒指香港生物科技指数报告: 2023-2030中国肿瘤药物市场复合年增长将达12.4%
Zhi Tong Cai Jing·2025-10-27 06:00